Francisco Javier Caballero-Granado

Francisco Javier Caballero-Granado

Auto-generated profile, based on publicly available information

Francisco Javier Caballero-Granado

Sección de Enfermedades Infecciosas, Hospital Punta de Europa, Algeciras, Cádiz, Spain

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1996 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JCJosé M. Cisneros
José M. Cisneros
MRMaria J. Reyes
Maria J. Reyes
JPJerónimo Pachón
Jerónimo Pachón
BBBerta Becerril
Berta Becerril
FCFrancisco J. Caballero
Francisco J. Caballero
ACAdelaido R. Cobacho
Adelaido R. Cobacho
The number of nosocomial infections caused by Acinetobacter baumannii has increased in recent years. During a 12-month study, there were 1.8 episodes of A. baumannii bacteremia per 1,000 adults admitted to a hospital in Seville, Spain. Seventy-nine patients were included in the study. A. baumannii bacteremia occurred after a mean (± SD) hospitalization of 18 ± 20 days. In all cases the infections were acquired nosocomially; 71% were acquired in intensive care units. Ampicillinl sulbactam was found to be the most active agent against A. baumannii. The most common source of the bacteremia was the respiratory tract (32 cases [71%n. Twenty patients (25%) had septic shock, and 24 (30%) had disseminated intravascular coagulation (DIC). Treatment with imipenem or ampicillinlsulbactam was most effective (cure rates, 87.5% and 83%, respectively). The deaths of 27 patients (34%) were related to A. baumannii bacteremia. The presence of DIC (odds ratio [OR] = 116.4; P < .0001) and inappropriate antimicrobial treatment (OR = 15.2; P < .01) were independently associated with mortality. We conclude that most A. baumannii isolates are multiresistant and that nosocomial A. baumannii bacteremia may cause severe clinical disease that is associated with a high mortality.

30 March 2005 in Hepatology
Verified
Journal Article
Open access
PDF file
JPJuan A Pineda
Juan A Pineda
MRManuel Romero-Gómez
Manuel Romero-Gómez
FDFernando Díaz-García
Fernando Díaz-García
José-Antonio Girón-GonzálezJosé-Antonio Girón-González
José-Antonio Girón-González
JMJosé L Montero
José L Montero
GHGrupo Andaluz Para El Estudio Del Hígado
Grupo Andaluz Para El Estudio Del Hígado
The impact of human immunodeficiency virus (HIV) coinfection on the survival of patients with hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is unknown. Because HIV infection is no longer considered an absolute contraindication for liver transplantation in some countries, it has become a priority to address this topic. The objective of this study was to compare the survival of HIV‐infected and HIV‐uninfected patients with decompensated cirrhosis due to HCV. In a retrospective cohort study, the survival of 1,037 HCV monoinfected and 180 HCV/HIV‐coinfected patients with cirrhosis after the first hepatic decompensation was analyzed. Of the group, 386 (37%) HCV‐monoinfected and 100 (56%) HCV/HIV‐coinfected subjects died during the follow‐up. The median survival time of HIV‐infected and HIV‐uninfected patients was 16 and 48 months, respectively (P < .001). The relative risk (95% CI) of death for HIV‐infected patients was 2.26 (1.51‐3.38). Other independent predictors of survival were age older than 63 years (2.25 [1.53‐3.31]); Child‐Turcotte‐Pugh class B versus class A (1.95 [1.41–2.68]) and class C versus class A (2.78 [1.66–4.70]); hepatitis D virus infection (1.56 [1.12–4.77]); model for end‐stage liver disease score, (1.05 [1.01‐1‐11]); more than one simultaneous decompensation (1.23 [1.12–3.33]); and the type of the first hepatic decompensation, with a poorer prognosis associated with encephalopathy compared with portal hypertensive gastrointestinal bleeding (2.03 [1.26–3.10]). In conclusion, HIV coinfection reduces considerably the survival of patients with HCV‐related ESLD independently of other markers of poor prognosis. This fact must be taken into account to establish the adequate timing of liver transplantation in HIV‐coinfected subjects. (HEPATOLOGY 2005.)

15 February 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FCF. J. Caballero-Granado
F. J. Caballero-Granado
BBB. Becerril
B. Becerril
LCL. Cuberos
L. Cuberos
MBMáximo Bernabeu-Wittel
Máximo Bernabeu-Wittel
JCJosé M. Cisneros
José M. Cisneros
JPJerónimo Pachón
Jerónimo Pachón
The mortality rate of patients with cases of enterococcal bacteremia is high, although it has often been related to the patients' underlying conditio

1 April 2000 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MRM.-J. Rodriguez-Hernandez
M.-J. Rodriguez-Hernandez
JPJerónimo Pachón
Jerónimo Pachón
CPCristina Pichardo
Cristina Pichardo
LCLucila Cuberos
Lucila Cuberos
JIJosé Ibáñez-Martínez
José Ibáñez-Martínez
ANAndrés
Andrés
Acinetobacter baumannii is a common cause of nosocomial pneumonia and other nosocomial infections. Multiresistant A. baumannii has also a high prevalence, which can make effective treatment difficult. We designed a new model of A. baumannii experimental pneumonia using C57BL/6 immunocompetent mice. This model was used to compare the efficacy of imipenem, doxycycline and amikacin in monotherapy, and the combination of imipenem plus amikacin and doxycycline plus amikacin. Doxycycline plus amikacin were synergic in vitro after 24 h incubation, whereas imipenem plus amikacin showed no in vitro synergy. The number of sterile lungs and the lung clearance of A. baumannii were greater in the group treated with imipenem than in those treated with amikacin or doxycycline in monotherapy (P < 0.05). The combination of imipenem plus amikacin and doxycycline plus amikacin was no more effective than imipenem alone in the clearance of organisms from lungs (2.42 ± 1.46 cfu/g versus 2.7 ± 1.5 cfu/g versus 1.23 ± 1.02 cfu/g). These results suggest that the addition of amikacin does not improve the results obtained by imipenem monotherapy. Doxycycline plus amikacin is an alternative to imipenem in the therapy of A. baumannii pneumonia.

26 April 1999 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
MBMáximo Bernabeu-Wittel
Máximo Bernabeu-Wittel
JPJerónimo Pachón
Jerónimo Pachón
AAA. Alarcón
A. Alarcón
LCLuis Fernando Lopez Cortes
Luis Fernando Lopez Cortes
PVP. Viciana
P. Viciana
FCF. J. Caballero-Granado
F. J. Caballero-Granado
MURINE TYPHUS (MT), a zoonosis that is caused by Rickettsia typhi, occurs all over the world, with endemic areas in North and South America, Southeast Asia, Africa, Australia, and some southern European countries.1-10 The importance of this illness has been underestimated. It is more frequent than is commonly believed and represents a worldwide health problem.11 Studies on its prevalence have shown that it also occurs in Spain.12,13 Sporadic cases have been reported in Seville, Huelva, and Murcia,7-9 but, to our knowledge, no extensive studies have been performed to investigate its clinical and epidemiological characteristics. Therefore, its real incidence is not known.

1 April 2001 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MRMaría-Jesús Rodríguez-Hernández
María-Jesús Rodríguez-Hernández
LCLucila Cuberos
Lucila Cuberos
CPCristina Pichardo
Cristina Pichardo
FCFrancisco J. Caballero
Francisco J. Caballero
IMIgnacio Moreno
Ignacio Moreno
JPJerónimo Pachón
Jerónimo Pachón
Sulbactam and imipenem were compared in an experimental pneumonia model in immunocompetent mice, using a susceptible strain of Acinetobacter baumannii, and in an experimental endocarditis model in rabbits, using an intermediately susceptible strain. In the former, sulbactam was as efficacious as imipenem in terms of survival, sterility of lungs and in the bacterial clearance from lungs and blood, provided that the t > MIC for sulbactam (1.84 h) was similar to that for imipenem (2.01 h). In the endocarditis model, imipenem (t > MIC, 2.12 h) was more efficacious than sulbactam (t > MIC, 1.17 h) in bacterial clearance from vegetations. These results show the efficacy of sulbactam in infections caused by susceptible strains of A. baumannii, with an MIC up to 4 mg/L, provided that doses reach a t > MIC similar to that of imipenem. The activity of sulbactam was time dependent.